Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Alefacept does not effectively treat severe alopecia areata.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.

Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

This therapy effectively treats resistant alopecia areata with minimal side effects.

COVID-19 doesn't make alopecia areata worse.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.

Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.

Japanese patients with alopecia areata often have a higher BMI and consume more vitamin C, fruit, and retinol, which may affect their condition's development or severity.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

Higher IL-37 levels are linked to more severe alopecia areata, but the gene variation doesn't affect disease risk.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.

A woman lost all her hair after mild COVID-19, but it started to regrow after treatment with a specific medication.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.